Minaris, a leading global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy (CGT), has announced a major strategic restructuring. The company is launching a dedicated viral vectors business unit, a move that fundamentally redefines its operational model to focus on three core pillars: viral vectors, cell therapies, and advanced testing.
This organizational shift is designed to align the company more closely with the rapidly evolving demands of the biopharmaceutical industry. By centralizing its viral vector expertise—which is anchored in its Philadelphia facilities—Minaris aims to deepen its specialized capabilities while ensuring a seamless, coordinated experience across the entire product lifecycle, from initial development and quality assurance to large-scale commercial manufacturing.
The decision to carve out a standalone viral vectors unit reflects a broader industry trend toward in-vivo gene therapies. As biotechnology pipelines increasingly prioritize these complex treatments, the availability of robust, scalable viral vector development has become a critical bottleneck and a primary driver of success. Minaris intends to address this by offering comprehensive support that includes lentiviral technologies, technology transfer, and rigorous adherence to current good manufacturing practice (cGMP).
“The addition of a dedicated Viral Vectors business unit allows us to bring greater focus to this critical area,” said Minaris CEO Orla Cloak. “Our goal is to provide the technical expertise and integrated capabilities customers need to move complex therapies from development through commercialization.”
To spearhead this new structure, Minaris has appointed a team of veteran leaders to guide its business units. Eytan Abraham, PhD, has been tapped to lead the new Viral Vectors division. He will be joined by Ilya Koltover, PhD, who will oversee Advanced Testing, and Luciana Mansolelli, PharmD, who will head the Cell Therapies unit.
According to Minaris, the new structure provides clients with the flexibility to engage with one or multiple business units depending on the specific requirements of their therapeutic programs. This integration is designed to maintain high standards in biosafety and analytical testing, which the company identifies as essential components for the next generation of life-saving treatments.
As the CGT landscape shifts toward more sophisticated in-vivo platforms, the need for agile, high-quality manufacturing partners has never been greater. With this move, Minaris is positioning itself as a central player in the race to bring these complex therapies to market, signaling that the ability to reliably produce viral vectors will be the key differentiator for CDMOs in the coming years. By consolidating its expertise into specialized units, Minaris aims to provide the stability and technical depth required to help its customers navigate the challenging path from the laboratory to the bedside.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
